Literature DB >> 23096078

Myocardial 123I-MIBG scintigraphy predicts an impairment in myocardial functional reserve during dobutamine stress in patients with idiopathic dilated cardiomyopathy.

Satoru Ohshima1, Satoshi Isobe, Daisuke Hayashi, Shinji Abe, Katsuhiko Kato, Toyoaki Murohara.   

Abstract

PURPOSE: We investigated whether myocardial (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy predicts impairment of myocardial functional reserve in response to dobutamine stress in patients with idiopathic dilated cardiomyopathy (DCM).
METHODS: Forty DCM patients (LVEF 39 ± 12 %) underwent myocardial (123)I-MIBG scintigraphy, echocardiography, and cardiac catheterization. Myocardial (123)I-MIBG uptake was quantified as the delayed heart to mediastinum (H/M) ratio and washout rate (WR). Local denervation was evaluated on polar map images. LV dP/dt (max) and T(1/2) were determined from left ventricular pressure curves at baseline and during dobutamine infusion (15 μg/kg /min). Patients were classified into two groups as follows: group A comprised 21 patients showing a delayed H/M ratio of <1.9 (median value); group B comprised 19 patients showing a delayed H/M ratio of ≥ 1.9.
RESULTS: The percentage change in heart rate (%HR), LV dP/dt (max) (%LV dP/dt (max)), and T (1/2) (%T (1/2)) from baseline to dobutamine stress were significantly more reduced in group A than in group B (39.3 ± 20.2 %, 55.2 ± 24.1 %, p < 0.01; 102.3 ± 46.3 %, 152.0 ± 72.3 %, p < 0.05; 38.7 ± 15.3 %, 46.9 ± 15.4 %, p < 0.05, respectively). No significant differences between the two groups were observed in the echocardiographic parameters or baseline cardiac catheterization parameters. Significant correlations were found between delayed H/M ratio and %HR (r = 0.35, p < 0.05), %LV dP/dt (max) (r = 0.45, p < 0.05) and %T (1/2) (r = 0.34, p < 0.05). Significant inverse correlations were also found between WR and %HR (r = -0.37, p < 0.05), %LV dP/dt (max) (r = -0.60, p < 0.0001), and %T (1/2) (r = -0.34, p < 0.05). SPECT images revealed enhanced denervation from the inferoposterior to anterior wall in accordance with the advancement of global denervation.
CONCLUSION: Reduced (123)I-MIBG uptake and increased washout were related to impairment in adrenergic myocardial functional reserve in idiopathic DCM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096078     DOI: 10.1007/s00259-012-2256-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.

Authors:  P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

Review 2.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

3.  Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment.

Authors:  Shinichiro Fujimoto; Aritomo Inoue; Shinji Hisatake; Shohei Yamashina; Hisayo Yamashina; Hajime Nakano; Junichi Yamazaki
Journal:  Nucl Med Commun       Date:  2005-02       Impact factor: 1.690

4.  Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy.

Authors:  M Suwa; Y Otake; A Moriguchi; T Ito; Y Hirota; K Kawamura; I Adachi; I Narabayashi
Journal:  Am Heart J       Date:  1997-03       Impact factor: 4.749

5.  Histological study on the distribution of autonomic nerves in the human heart.

Authors:  Hiroaki Kawano; Ryozo Okada; Katsusuke Yano
Journal:  Heart Vessels       Date:  2003-03       Impact factor: 2.037

6.  Dobutamine stress testing as a diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy.

Authors:  Masakazu Kobayashi; Hideo Izawa; Xian Wu Cheng; Hiroyuki Asano; Akihiro Hirashiki; Kazumasa Unno; Satoru Ohshima; Takashi Yamada; Yosuke Murase; Tomoko S Kato; Koji Obata; Akiko Noda; Takao Nishizawa; Satoshi Isobe; Kohzo Nagata; Tatsuaki Matsubara; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  JACC Cardiovasc Imaging       Date:  2008-11

7.  Prognostic value of pharmacologic stress echocardiography in patients with idiopathic dilated cardiomyopathy: a prospective, head-to-head comparison between dipyridamole and dobutamine test.

Authors:  Lorenza Pratali; Petar Otasevic; Aleksandar Neskovic; Sabrina Molinaro; Eugenio Picano
Journal:  J Card Fail       Date:  2007-12       Impact factor: 5.712

8.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

9.  Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy.

Authors:  Myron C Gerson; Nancy McGuire; Lynne E Wagoner
Journal:  J Card Fail       Date:  2003-10       Impact factor: 5.712

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.